WO2011016861A2 - Nouvelles protéines régulatrices et nouveaux inhibiteurs - Google Patents
Nouvelles protéines régulatrices et nouveaux inhibiteurs Download PDFInfo
- Publication number
- WO2011016861A2 WO2011016861A2 PCT/US2010/002173 US2010002173W WO2011016861A2 WO 2011016861 A2 WO2011016861 A2 WO 2011016861A2 US 2010002173 W US2010002173 W US 2010002173W WO 2011016861 A2 WO2011016861 A2 WO 2011016861A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gsap
- imatinib
- peptide
- secretase
- disease
- Prior art date
Links
- 0 CC(c(cc(C)c(*=C=C)c1)c1OC)=O Chemical compound CC(c(cc(C)c(*=C=C)c1)c1OC)=O 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Cc(ccc(NC(c1ccc(CN2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2cccnc2)ccn1 Chemical compound Cc(ccc(NC(c1ccc(CN2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2cccnc2)ccn1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- GWHJZXXIDMPWGX-UHFFFAOYSA-N Cc1ccc(C)c(C)c1 Chemical compound Cc1ccc(C)c(C)c1 GWHJZXXIDMPWGX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Definitions
- the A ⁇ 40 form is not associated with early deposits of amyloid plaques.
- the A ⁇ 42 form accumulates early and predominantly in the parenchymal plaques and there is strong evidence that A ⁇ 42 plays a major role in amyloid plaque deposits in familial Alzheimer's disease patients.
- Neurofibrillary tangles consist of aggregated tau protein and their role in AD pathology is less clear.
- AD symptoms are most closely correlated with total brain A ⁇ rather than plaques.
- About 10% of AD cases result from autosomal dominant inheritance of mutations in either the APP or the presenilin 1 and presenilin 2 genes. In both cases, increased production of total A ⁇ or A ⁇ 42 versus A ⁇ 40 results.
- APP-CTF is the truncated form of APP- ⁇ -CTF spanning from its N-terminus to HHGV 64 .
- APP-CTF-T2 is the truncated form of APP- ⁇ -CTF spanning from its N- terminus to VMLKK 55 . Truncated forms are overexpressed in HEK293 cells and
- gSAP In contrast to some other regulators of ⁇ -secretase activity, gSAP is selective and influences cleavage of APP but not of Notch. Although the mechanism of substrate selection by ⁇ -secretase remains unclear, a number of other proteases and phosphatases with broad substrate recognition can achieve specificity through auxiliary factors that couple the core enzyme to a subset of substrates. To determine the mechanism by which gSAP might confer such specificity, we analyze its binding to specific substrates in HEK293 cells. gSAP- 16K immunoprecipitates with APP-CTF but not with Notch ⁇ E.
- the invention provides
- gSAP monoclonal antibodies to gSAP, e.g., capable of inhibiting its interaction with gamma-secretase and so inhibiting or reducing as A ⁇ production and accumulation;
- the invention additionally provides a method of identifying persons at risk of developing AD comprising checking for elevated expression levels and/or mutations in gSAP relative to normal values as identified using a control population.
- a method for producing an inhibitory effect against the accumulation of abnormal protein aggregates in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
- the present invention provides methods of treatment of
- RNA molecules e.g. recombinant adeno-associated virus 2 (AA V2) carrying gSAP shRNA;
- DIPEA iV,iV-Diisopropylethylamine
- membrane pellets are prepared as described above and resuspended in 50 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM MgCl 2 , 5 mM CaCl 2 .
- human embryonic kidney cells (HEK293) grown to -80% confluency ( ⁇ 10 7 cells) are incubated with 0.1 ⁇ M 3 H-GOl in Opti-MEM for 2 hours in an incubator at 37 0 C, with 5% CO 2 before being transferred to ice for an additional hour. Medium is removed and cells are washed twice with cold phosphate buffered saline (PBS), pH 7.4. Photolysis is conducted on ice for 2 min using a compact UV lamp (4 watt, model UVGL-25, UVP Inc.) at 254 nM. As controls, cells are incubated either without UV crosslinking or in the presence of 50 ⁇ M unlabeled imatinib.
- PBS cold phosphate buffered saline
- Example 8 In vitro ⁇ -secretase assay.
- Immunoprecipitation of APP-CTF, but not of Notch ⁇ E, is associated with co- immunoprecipitation of gSAP-16K. Treatment with imatinib reduces the association between gSAP-16K and APP-CTF.
- TGCTGTTGACAGTGAGCGCGGGTATAGCCTTATTTGCATATAGTGAAGCCACAGA TGTATATGCAAATAAGGCTATACCCATGCCTACTGCCTCGGA ) ispurchased from Openbiosystems/Thermo Scientific.
- the hairpin region is excised and inserted into AA V2- siln4.1 -MCS-EGFP vector (Vector biolabs) via BamHI and HindIII sites.
- the triple transgenic AD mice (6 months old) are analyzed for A ⁇ .
- the double transgenic AD mice (13 months old) are analyzed for plaques.
- the membrane is pelleted down, solubilized in 50 mM Hepes, 150 mM NaCl, 1% octyl ⁇ -D-glucopyranoside, and bound to Myone streptavidin Tl beads for 1 hr, then washed 3 times.
- the captured protein is released by incubation with SDS sample buffer and detected by western blot.
Abstract
L'invention porte sur une protéine jusqu'à présent non caractérisée (protéine d'activation de gamma-secrétase ou gSAP) qui active la γ-secrétase pour produire une protéine β-amyloïde (Aβ). Le dépôt d'Aβ a été associé à la maladie d'Alzheimer et à d'autres pathologies. Ainsi, l'invention porte, de plus, par exemple, sur des procédés de criblage et de nouveaux outils de recherche, sur des inhibiteurs de cette nouvelle protéine et sur des procédés de diagnostic, de traitement et de lutte contre la maladie d'Alzheimer et autres états neurodégénératifs associés au dépôt d'Aβ.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10806753.9A EP2461673A4 (fr) | 2009-08-05 | 2010-08-05 | Nouvelles protéines régulatrices et nouveaux inhibiteurs |
SG2012008215A SG178279A1 (en) | 2009-08-05 | 2010-08-05 | Novel regulatory proteins and inhibitors |
JP2012523606A JP6166534B2 (ja) | 2009-08-05 | 2010-08-05 | 新規調節タンパク質および阻害剤 |
US13/367,049 US9605041B2 (en) | 2009-08-05 | 2012-02-06 | Regulatory proteins and inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23146209P | 2009-08-05 | 2009-08-05 | |
US61/231,462 | 2009-08-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/367,049 Continuation US9605041B2 (en) | 2009-08-05 | 2012-02-06 | Regulatory proteins and inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011016861A2 true WO2011016861A2 (fr) | 2011-02-10 |
WO2011016861A3 WO2011016861A3 (fr) | 2012-08-23 |
Family
ID=43544826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/002173 WO2011016861A2 (fr) | 2009-08-05 | 2010-08-05 | Nouvelles protéines régulatrices et nouveaux inhibiteurs |
Country Status (5)
Country | Link |
---|---|
US (1) | US9605041B2 (fr) |
EP (1) | EP2461673A4 (fr) |
JP (2) | JP6166534B2 (fr) |
SG (2) | SG178279A1 (fr) |
WO (1) | WO2011016861A2 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013067157A1 (fr) * | 2011-11-01 | 2013-05-10 | Modgene, Llc | Compositions et méthodes de réduction de la charge amyloïde-bêta |
WO2013163423A1 (fr) * | 2012-04-25 | 2013-10-31 | Musc Foundation For Research Development | Compositions et procédés pour la guérison des plaies et la réparation tissulaire |
US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
US10131671B2 (en) | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10238660B2 (en) | 2009-05-13 | 2019-03-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
US11759465B2 (en) | 2018-01-31 | 2023-09-19 | Intra-Cellular Therapies, Inc. | Uses |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102234112B1 (ko) * | 2014-06-27 | 2021-04-02 | 한양대학교 산학협력단 | 뇌 특이적 핵산 전달 |
JP6994715B2 (ja) * | 2017-10-04 | 2022-02-04 | 国立大学法人京都大学 | Bcr-Ablタンパク質イメージング用分子プローブ |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
WO2003057165A2 (fr) | 2002-01-04 | 2003-07-17 | The Rockefeller University | Compositions et procedes de prevention et de traitement de troubles lies au peptide beta-amyloide |
WO2004005281A1 (fr) | 2002-07-05 | 2004-01-15 | Novartis Ag | Inhibiteurs de tyrosine kinases |
US20040171823A1 (en) | 2003-01-14 | 2004-09-02 | Nadler Steven G. | Polynucleotides and polypeptides associated with the NF-kappaB pathway |
WO2004110452A1 (fr) | 2003-06-13 | 2004-12-23 | Novartis Ag | Derives de 2-aminopyrimidine utilises comme inhibiteurs de raf kinase |
WO2005039586A1 (fr) | 2003-10-27 | 2005-05-06 | Novartis Ag | Utilisation de derives de pyridinyle-pyrimidinylamino-benzamide pour traiter des troubles associes a l'amyloide |
EP1533304A1 (fr) | 2002-06-28 | 2005-05-25 | Nippon Shinyaku Co., Ltd. | Derive d'amide |
WO2005072826A2 (fr) | 2004-01-21 | 2005-08-11 | Emory University | Compositions et procedes pour utiliser des inhibiteurs de tyrosine kinase afin de traiter une infection pathogenique |
WO2008057599A2 (fr) | 2006-11-10 | 2008-05-15 | Intra-Cellular Therapies, Inc. | Procédés de traitement de troubles associés à l'abeta et compositions |
WO2008153959A1 (fr) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Nouveaux composés hétérocycliques et utilisations associées |
WO2008153974A1 (fr) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Nouveaux composés hétérocycliques et utilisations associées |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6032638B2 (ja) | 1976-09-01 | 1985-07-29 | 武田薬品工業株式会社 | 3−アミノピラゾロ〔3,4−d〕ピリミジン誘導体 |
WO1982003626A1 (fr) | 1981-04-22 | 1982-10-28 | Gauri Kailash Kumar | Nouveaux derives de la pyrazolo (3, 4-d) pyrimidine, procede de leur preparation et remede les contenant |
HU186891B (en) | 1981-06-12 | 1985-10-28 | Richter Gedeon Vegyeszet | Process for producing esters of apovincaminic acid |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
IL98559A0 (en) | 1990-06-21 | 1992-07-15 | Schering Corp | Polycyclic guanine derivatives |
US5272055A (en) | 1991-12-24 | 1993-12-21 | The University Of Kentucky Research Foundation | Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US20020006963A1 (en) | 1992-06-23 | 2002-01-17 | Young James W. | Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds |
TW270118B (fr) | 1993-02-26 | 1996-02-11 | Schering Corp | |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
EP0723533A1 (fr) | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyle-n-arylpyrimidinamines et leurs derives |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
US5798246A (en) | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
US5777195A (en) | 1996-05-17 | 1998-07-07 | The Rockefeller University | Knockout mutant mouse for DARPP-32 and use thereof |
GB9610964D0 (en) | 1996-05-24 | 1996-07-31 | Pharmacia & Upjohn Spa | Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors |
JPH1143499A (ja) | 1996-09-11 | 1999-02-16 | Takeda Chem Ind Ltd | 新規タンパク質およびそのdna |
US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
US6057329A (en) | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
TW584622B (en) | 1996-12-24 | 2004-04-21 | Chugai Pharmaceutical Co Ltd | Aromatic amine derivatives having NOS inhibitory effect |
SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
WO1999001439A1 (fr) | 1997-07-03 | 1999-01-14 | Du Pont Pharmaceuticals Company | Heterocycles aryl- et arylamino-substitues utilises comme antagonistes de l'hormone corticotrope |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
WO1999020273A1 (fr) | 1997-10-17 | 1999-04-29 | The Rockefeller University | Traitement de la schizophrenie par utilisation d'un inhibiteur de la dephosphorylation de la darpp-32 |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
WO1999051582A1 (fr) | 1998-03-31 | 1999-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques azotes |
US6133273A (en) | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
BR9913850A (pt) | 1998-09-17 | 2001-10-23 | Otsuka Pharma Co Ltd | Gene ly6h |
US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
JP2000224992A (ja) | 1998-11-30 | 2000-08-15 | Tanabe Seiyaku Co Ltd | 新規ホスホジエステラーゼ及びその遺伝子 |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
EP1190070A1 (fr) | 1999-06-25 | 2002-03-27 | Memory Pharmaceutical Corporation | Isoformes de phosphodiesterase de l'amp cyclique et procedes d'utilisation |
WO2001000214A1 (fr) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Composes inhibiteurs de la kinase src |
CA2383546A1 (fr) | 1999-06-30 | 2001-01-04 | William H. Parsons | Composes inhibiteurs de la src kinase |
DE19931206A1 (de) | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
ATE309241T1 (de) | 1999-09-10 | 2005-11-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
AU7597000A (en) * | 1999-09-21 | 2001-04-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Imaging of drug accumulation as a guide to antitumor therapy |
US6372743B1 (en) | 1999-09-30 | 2002-04-16 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines |
US20020147197A1 (en) | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
CN1378547A (zh) | 1999-10-11 | 2002-11-06 | 辉瑞大药厂 | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4,3-d]嘧啶-7-酮类化合物 |
IL152925A (en) | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
AU2005201482A1 (en) | 1999-11-08 | 2005-05-05 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
WO2001056567A1 (fr) | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | Derives de 2,4-diaminothiazole |
US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
US6333167B1 (en) | 2000-03-10 | 2001-12-25 | American Home Products Corp. | Methods and reagents for identifying inhibitors of proteolysis of membrane-associated proteins |
EP1136485A1 (fr) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | Dérivés d' aminophénylpyrimidinone |
US6713248B2 (en) | 2000-04-03 | 2004-03-30 | Bristol-Myers Squibb Company | Methods for detection of gamma-secretase activity and identification of inhibitors thereof |
EP1289966A1 (fr) | 2000-04-11 | 2003-03-12 | Bristol-Myers Squibb Pharma Company | LACTAMES SUBSTITUES UTILISES EN TANT QU'INHIBITEURS DE PRODUCTION DE PROTEINE A$g(b) |
CA2406383A1 (fr) | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Agents de reduction de a.beta.42 |
AU2001255849B8 (en) | 2000-04-19 | 2006-04-27 | Lilly Icos, Llc. | PDE-V inhibitors for treatment of Parkinson's Disease |
DE60123074T3 (de) | 2000-05-11 | 2015-01-29 | Scios Inc. | Modulation von gamma-secretase aktivität |
TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
US7320785B2 (en) | 2001-08-10 | 2008-01-22 | The Rockefeller University | Compositions and methods for modulation of DARPP-32 phosphorylation |
CN1781920A (zh) | 2001-08-28 | 2006-06-07 | 先灵公司 | 多环鸟嘌呤磷酸二酯酶v抑制剂 |
US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
US6649908B2 (en) | 2001-09-20 | 2003-11-18 | Agilent Technologies, Inc. | Multiplexing capillary array for atmospheric pressure ionization-mass spectrometry |
HUP0401998A2 (hu) | 2001-11-02 | 2005-01-28 | Pfizer Products Inc., | PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
MXPA04004370A (es) | 2001-11-09 | 2004-08-11 | Schering Corp | Derivados policiclicos de guanina inhibidores de fosfodiesterasa v. |
NZ535354A (en) | 2002-02-15 | 2008-01-31 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
CA2477253A1 (fr) | 2002-02-21 | 2003-09-04 | The Rockefeller University | Compositions et methodes de regulation de la signalisation dependant du calcium dans le cerveau |
SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
WO2004087906A1 (fr) | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Structure cristalline de 3',5'-phosphodiesterase nucleotidique cyclique 1d(pde1b) et ses utilisations |
CA2517487A1 (fr) | 2003-04-01 | 2004-10-14 | Applied Research Systems Ars Holding N.V. | Inhibiteurs de phosphodiesterases dans l'infecondite |
WO2005019258A2 (fr) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
BRPI0611095B8 (pt) | 2005-06-06 | 2021-05-25 | Intracellular Therapies Inc | compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos |
GB0512091D0 (en) * | 2005-06-14 | 2005-07-20 | Novartis Ag | Organic compounds |
WO2007025103A2 (fr) | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Composes organiques |
EP2023729B1 (fr) | 2006-06-06 | 2016-05-04 | Intra-Cellular Therapies, Inc. | Composés organiques |
US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
EP2081431B1 (fr) | 2006-11-13 | 2013-01-16 | Intra-Cellular Therapies, Inc. | Composés organiques |
EP2089034A4 (fr) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | Nouvelles utilisations |
KR20120012831A (ko) | 2007-12-06 | 2012-02-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
CN101969774A (zh) | 2007-12-06 | 2011-02-09 | 细胞内治疗公司 | 有机化合物 |
WO2010132127A1 (fr) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Composés organiques |
-
2010
- 2010-08-05 EP EP10806753.9A patent/EP2461673A4/fr not_active Withdrawn
- 2010-08-05 SG SG2012008215A patent/SG178279A1/en unknown
- 2010-08-05 WO PCT/US2010/002173 patent/WO2011016861A2/fr active Application Filing
- 2010-08-05 JP JP2012523606A patent/JP6166534B2/ja not_active Expired - Fee Related
- 2010-08-05 SG SG10201507362TA patent/SG10201507362TA/en unknown
-
2012
- 2012-02-06 US US13/367,049 patent/US9605041B2/en active Active
-
2015
- 2015-11-06 JP JP2015218065A patent/JP2016102110A/ja active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
WO2003057165A2 (fr) | 2002-01-04 | 2003-07-17 | The Rockefeller University | Compositions et procedes de prevention et de traitement de troubles lies au peptide beta-amyloide |
EP1533304A1 (fr) | 2002-06-28 | 2005-05-25 | Nippon Shinyaku Co., Ltd. | Derive d'amide |
WO2004005281A1 (fr) | 2002-07-05 | 2004-01-15 | Novartis Ag | Inhibiteurs de tyrosine kinases |
US20040171823A1 (en) | 2003-01-14 | 2004-09-02 | Nadler Steven G. | Polynucleotides and polypeptides associated with the NF-kappaB pathway |
WO2004110452A1 (fr) | 2003-06-13 | 2004-12-23 | Novartis Ag | Derives de 2-aminopyrimidine utilises comme inhibiteurs de raf kinase |
WO2005039586A1 (fr) | 2003-10-27 | 2005-05-06 | Novartis Ag | Utilisation de derives de pyridinyle-pyrimidinylamino-benzamide pour traiter des troubles associes a l'amyloide |
WO2005072826A2 (fr) | 2004-01-21 | 2005-08-11 | Emory University | Compositions et procedes pour utiliser des inhibiteurs de tyrosine kinase afin de traiter une infection pathogenique |
WO2008057599A2 (fr) | 2006-11-10 | 2008-05-15 | Intra-Cellular Therapies, Inc. | Procédés de traitement de troubles associés à l'abeta et compositions |
WO2008153959A1 (fr) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Nouveaux composés hétérocycliques et utilisations associées |
WO2008153974A1 (fr) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Nouveaux composés hétérocycliques et utilisations associées |
Non-Patent Citations (5)
Title |
---|
CANCINO ET AL., BRAIN, vol. 131, 2008, pages 2425 - 2442 |
J. ZIMMERMANN ET AL., BIOORGANIC & MEDICINAL CHEM. LETT., vol. 7, no. 2, pages 187 - 192 |
NETZER ET AL., PNAS, 14 October 2003 (2003-10-14), pages 12444 - 12449 |
NETZER ET AL., PROC NATL ACAD SCI., vol. 100, no. 21, 2003, pages 12444 - 9 |
See also references of EP2461673A4 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10238660B2 (en) | 2009-05-13 | 2019-03-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9707231B2 (en) | 2011-11-01 | 2017-07-18 | Modgene, Llc | Compositions and methods for reduction of amyloid-beta load |
US10258623B2 (en) | 2011-11-01 | 2019-04-16 | Modgene, Llc | Compositions and methods for reduction of amyloid-beta load |
JP2014532711A (ja) * | 2011-11-01 | 2014-12-08 | モッドジーン リミテッド ライアビリティ カンパニーModgene,Llc | アミロイドβ負荷を低減するための組成物および方法 |
WO2013067157A1 (fr) * | 2011-11-01 | 2013-05-10 | Modgene, Llc | Compositions et méthodes de réduction de la charge amyloïde-bêta |
AU2012332416B2 (en) * | 2011-11-01 | 2017-06-15 | Modgene, Llc | Compositions and methods for reduction of amyloid-beta load |
US10092624B2 (en) | 2012-04-25 | 2018-10-09 | Musc Foundation For Research Development | Methods of treating cancers with peptide-based modulators |
US9345744B2 (en) | 2012-04-25 | 2016-05-24 | Musc Foundation For Research Development | Peptide-based collagen modulators for wound healing and tissue repair |
JP2015515282A (ja) * | 2012-04-25 | 2015-05-28 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 創傷治癒および組織修復のための組成物および方法 |
WO2013163423A1 (fr) * | 2012-04-25 | 2013-10-31 | Musc Foundation For Research Development | Compositions et procédés pour la guérison des plaies et la réparation tissulaire |
US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
US10398698B2 (en) | 2013-02-17 | 2019-09-03 | Intra-Cellular Therapies, Inc. | Uses |
US10131671B2 (en) | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
US11166956B2 (en) | 2014-08-07 | 2021-11-09 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
US11759465B2 (en) | 2018-01-31 | 2023-09-19 | Intra-Cellular Therapies, Inc. | Uses |
US11839614B2 (en) | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
Also Published As
Publication number | Publication date |
---|---|
EP2461673A4 (fr) | 2013-08-07 |
US20130149309A1 (en) | 2013-06-13 |
JP2013500741A (ja) | 2013-01-10 |
EP2461673A2 (fr) | 2012-06-13 |
SG10201507362TA (en) | 2015-10-29 |
WO2011016861A3 (fr) | 2012-08-23 |
JP6166534B2 (ja) | 2017-07-19 |
US9605041B2 (en) | 2017-03-28 |
JP2016102110A (ja) | 2016-06-02 |
SG178279A1 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9605041B2 (en) | Regulatory proteins and inhibitors | |
Grabrucker et al. | The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation | |
Kovács et al. | Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies | |
JP3612078B2 (ja) | タウ−タウ会合の阻害 | |
Kosturko et al. | Heterogeneous nuclear ribonucleoprotein (hnRNP) E1 binds to hnRNP A2 and inhibits translation of A2 response element mRNAs | |
US20120214186A1 (en) | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING sAPPbeta | |
Liu et al. | Neuronal expression of ILEI/FAM3C and its reduction in Alzheimer’s disease | |
Maj et al. | Novel insights into the distribution and functional aspects of the calcium binding protein secretagogin from studies on rat brain and primary neuronal cell culture | |
Shekhar et al. | 5-LOX in Alzheimer’s disease: potential serum marker and in vitro evidences for rescue of neurotoxicity by its inhibitor YWCS | |
Wang et al. | BAP31 deficiency contributes to the formation of amyloid‐β plaques in Alzheimer's disease by reducing the stability of RTN3 | |
JP2004503747A (ja) | 結合物質の同定するための試薬と方法 | |
WO2014159244A2 (fr) | Anticorps tau d'o-glcnac et son utilisation | |
Hong et al. | Extraciliary roles of the ciliopathy protein JBTS17 in mitosis and neurogenesis | |
Schnöder et al. | P38α‐MAPK phosphorylates Snapin and reduces Snapin‐mediated BACE1 transportation in APP‐transgenic mice | |
KR20220075344A (ko) | 미토콘드리아 기능을 변형시키는 방법 및 화합물 | |
US20160368967A1 (en) | Methods and compositions for the inhibition of trpv4 | |
Niewiadomska et al. | Cytoskeletal transport in the aging brain: focus on the cholinergic system | |
Murthy et al. | Identification and characterization of a novel, shorter isoform of the small conductance Ca2+‐activated K+ channel SK2 | |
CN106794222B (zh) | 使用p75ecd和/或p75诊断或治疗神经障碍的方法 | |
JP2009524426A (ja) | ダブルコルチン様キナーゼ遺伝子の新規なmRNAスプライシング変異体及び神経外肺葉起源の癌の診断及び治療におけるその使用 | |
KR20070094947A (ko) | P25/cdk5 저해 화합물을 포함하는 퇴행성 뇌질환의 예방 및치료용 약학 조성물 | |
Hu et al. | PCP4 Promotes Alzheimer’s Disease Pathogenesis by Affecting Amyloid-β Protein Precursor Processing | |
JP5765688B2 (ja) | アクチン結合タンパク質の細胞運動関連疾患への利用 | |
WO2010092317A1 (fr) | Modulateur nnmnat2 | |
JP2022505101A (ja) | Nmda受容体媒介毒性を調節するための新規の方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10806753 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012523606 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010806753 Country of ref document: EP |